Revelation Biosciences Inc. Announces $9.1 Million Common Stock and Series A Financing
01/05/21, 11:04 PM
Location
menlo parkMoney raised
$9 million
Round Type
series a
Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today the closing of a non-brokered private placement financing, raising gross proceeds of $9.1 million. The financing was led by Global Health Investment Advisors. The Company sold 628,930 shares of Series A Preferred Stock and 808,877 shares of Common Stock at a purchase price of $6.36 per share (“Offering”).
Company Info
Location
menlo park, california, united states
Additional Info
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. The Company has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator for the early treatment of SARS-CoV-2 infection. An expansion of REVTx-99 therapeutic indications is planned, targeting early treatment and prevention of respiratory viral infection such as influenza A or B, parainfluenza, and respiratory syncytial virus. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to the Company’s therapeutic pipeline, Revelation is also developing REVDx-501, a rapid point of care diagnostic that can be used to detect any respiratory viral infection regardless of virus type without the need for specialized instrumentation. For more information on Revelation, please visit www.RevBiosciences.com.